MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Cognitive dysfunction"

  • MDS Virtual Congress 2021

    A Milestone-based approach to monitoring disease progression in Parkinson’s disease

    M. Brumm, A. Siderowf, T. Simuni, C. Caspell-Garcia, L. Chahine, T. Foroud, V. Arnedo, A. Reimer, C. Tanner, K. Poston, D. Weintraub, S. Hutten, K. Kieburtz, K. Marek, C. Coffey (Iowa City, USA)

    Objective: We used Parkinson Progression Marker Initiative (PPMI) data to assess the frequency of clinically meaningful disease milestones and examine baseline predictors of reaching these…
  • MDS Virtual Congress 2021

    Shannon entropy: a novel tool for assessing pentagon drawing in Parkinson’s disease

    L. Brabenec, P. Klobusiakova, J. Mekyska, I. Rektorova (Brno, Czech Republic)

    Objective: We used a digitizing tablet during PCT as a potential tool for assessing early cognitive deficits in PD yet without major cognitive impairment.  We…
  • MDS Virtual Congress 2021

    Cognitive Impairment in Parkinson’s disease Patients: a Descriptive Study

    R. Nindela, A. Kurniawan, Y. Harun, S. Marisdina, I. Irfannuddin (Palembang, Indonesia)

    Objective: This study aims to describe the cognitive profile in Parkinson's disease (PD) patients. Background: Cognitive impairment is a common non-motor symptom of PD. Cohort…
  • MDS Virtual Congress 2021

    Rapamycin attenuates nigral and hippocampal alpha-synuclein accumulation in AAV-mediated alpha-synuclein overexpression model of Parkinson’s disease

    E. Cinar, G. Yalcin-Cakmakli, A. Ulusoy, E. Saka, B. Tel, B. Elibol (Zonguldak, Turkey)

    Objective: To examine the possible neurorestorative effects of chronic rapamycin treatment in AAV-mediated alpha-synuclein (a-syn) overexpression model of Parkinson’s disease (PD), designed to induce hippocampal…
  • MDS Virtual Congress 2021

    Evaluation of bedside tests of attention in delirium superimposed on Parkinson’s disease and dementia

    R. Lawson, S. Richardson, D. Kershaw, D. Davis, B. Stephan, L. Robinson, C. Brayne, L. Barnes, D. Burn, A. Yarnall, JP. Taylor, S. Parker, L. Allan (Newcastle Upon Tyne, United Kingdom)

    Objective: To evaluate the ability of simple bedside tests for attention to detect delirium in those with and without underlying neurodegenerative diseases, including Parkinson’s disease…
  • MDS Virtual Congress 2021

    Single-Trajectory Multiple-Target Deep Brain Stimulation to treat Mobility and Cognition in Parkinson’s Disease: a Double-Blind, Randomized, Cross-Over Pilot Study

    S. Sasikumar, M. Cohn, I. Harmsen, A. Loh, S. Kalia, A. Lozano, A. Fasano (Toronto, Canada)

    Objective: To assess the benefit of deep brain stimulation (DBS) to improve cognition in Parkinson’s Disease (PD). Background: Patients with advanced PD suffer from both…
  • MDS Virtual Congress 2021

    Plasma phosphorylated α-synuclein relates to cognitive impairment in patients with Parkinson’s disease

    N-N. Che (Nangjing, China)

    Objective: To investigate whether plasma phosphorylated α-synuclein (p-syn) were associated with cognitive function in Parkinson’s disease (PD). Background: Parkinson’s disease (PD) is the second most…
  • MDS Virtual Congress 2021

    Dissociable contribution of serum NfL and p-tau181 to cognitive impairment and mild cognitive impairment in Parkinson’s disease.

    J. Pagonabarraga, R. Pérez-González, H. Bejr-Kasem, A. Horta-Barba, I. Aracil-Bolaños, S. Martinez-Horta, E. Rivas-Asensio, J. Perez-Perez, F. Sampedro, A. Campolongo, C. Izquierdo, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

    Objective: To analyze the contribution of serum NfL and p-tau181 levels to cognitive impairment and mild cognitive impairment (PD-MCI) in non-demented PD patients. Background: Autopsy…
  • MDS Virtual Congress 2021

    Close relationship between CSF lipidomic alterations and cognitive decline in Parkinson’s disease.

    Y. Mizutani, S. Shima, A. Ueda, M. Ito, H. Watanabe (Toyoake, Japan)

    Objective: To clarify what the lipidome of biological samples reflects in the pathology of Parkinson’s disease (PD). Background: The lipid pattern in the cerebrospinal fluid…
  • MDS Virtual Congress 2021

    The Neuropsychiatric Inventory:Assessment Of Neuropsychiatric Symptoms In Parkinson’s Disease

    GG. Uygun, GA. Yuksel, S. Kose (Istanbul, Turkey)

    Objective: We investigated the correlation of Neuropsychiatric Inventory(NPI) test score with progression of PD. Background: PD has characteristic motor symptoms and non-motor symptoms including psychiatric…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 117
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #25676 (not found)
  • Crack Dancing: An Uncommon Drug-Induced Chorea
  • #24376 (not found)
  • #24970 (not found)
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley